{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:52:19Z","timestamp":1791100339325,"version":"4.1.0"},"reference-count":16,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"unspecified","delay-in-days":1250,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec id=\"S0317167100012166_abs1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>It is controversial if distant recurrence of glioblastoma is more common after temozolomide (TMZ) concurrent with radiotherapy (RT). Optimal therapy for patients with recurrent disease after RT\/TMZ is unclear. Our purpose was to evaluate recurrence patterns in glioblastoma and the effect of treatment at recurrence upon survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167100012166_abs2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective review of 67 patients with newly diagnosed glioblastoma treated with RT\/TMZ between 2003-2007. Statistical analyses included Kaplan-Meier method for survival, and multivariate Cox proportional hazards model for the effect of salvage treatment on survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167100012166_abs3\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>58 patients (86.6%) recurred locally; 9 patients (13.4%) had a distant non-contiguous focus of new disease. Median survival(MS) was 17 months; median time-to-progression(TTP) 6.8 months. The local and distant groups had comparable prognostic factors. There was no difference in MS(p=0.35) or TTP(p=0.95) by location of recurrence. At relapse, 26 patients(38.8%) received continuous, dose-intense TMZ, 24(35.8%) other therapy(4.5% RT; 20.9% lomustine+\/-procarbazine; 4.5% etoposide; 1.5% conventional TMZ; 4.5% TMZ then lomustine), and 17(25.4%) were untreated. Dose-intense TMZ was associated with prolonged MS compared to all other patients(21.5 months vs. 12.4 months, p=0.019, HR=3.86, 95%CI: 1.81-8.22) and similar to MS with other chemotherapy regimens(18.8 months, p=0.40, HR=1.30, 95% CI: 0.65-2.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167100012166_abs4\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The pattern of recurrence of glioblastoma treated with RT\/TMZ was predominantly local. Second-line treatment with continuous dose-intense TMZ may prolong survival in patients with recurrent glioblastoma. Overall survival is similar to other conventional salvage regimens; however TMZ may be better tolerated. This study is limited by its retrospective nature and potential selection bias. Prospective controlled studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s0317167100012166","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T10:09:53Z","timestamp":1418378993000},"page":"621-625","source":"Crossref","is-referenced-by-count":59,"title":["Glioblastoma: Patterns of Recurrence and Efficacy of Salvage Treatments"],"prefix":"10.1017","volume":"38","author":[{"given":"Jiwon","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sanghera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May N.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,12,2]]},"reference":[{"key":"S0317167100012166_ref014","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600827"},{"key":"S0317167100012166_ref001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"S0317167100012166_ref004","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23813"},{"key":"S0317167100012166_ref007","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100009628"},{"key":"S0317167100012166_ref002","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.30.9.907"},{"key":"S0317167100012166_ref006","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2007.10.008"},{"key":"S0317167100012166_ref012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.4969"},{"key":"S0317167100012166_ref008","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.2366"},{"key":"S0317167100012166_ref011","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2008-058"},{"key":"S0317167100012166_ref003","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00266-1"},{"key":"S0317167100012166_ref013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.018"},{"key":"S0317167100012166_ref016","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5520"},{"key":"S0317167100012166_ref010","first-page":"1915","article-title":"Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase-3-activity and cleavage of focal adhesion kinase","volume":"62","author":"Wick","year":"2002","journal-title":"Cancer Res"},{"key":"S0317167100012166_ref015","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1369"},{"key":"S0317167100012166_ref005","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"S0317167100012166_ref009","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0596"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167100012166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T04:47:57Z","timestamp":1556340477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167100012166\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0317167100012166"],"URL":"https:\/\/doi.org\/10.1017\/s0317167100012166","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}